nintedanib

HRD status, KELIM, and TILs are key independent biomarkers in advanced OC. CCNE1 amplifications, although typically associated with platinum resistance, were linked to moderate chemotherapy sensitivity, defining an intermediate prognostic subgroup.

P3, N=92, Not yet recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

P1, N=24, Completed, PureTech | Not yet recruiting --> Completed

P=N/A, N=157, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting | N=493 --> 157

These include bosutinib, sorafenib, mitoxantrone, and nintedanib which are yet to be clinically investigated for vestibular schwannoma or meningioma. Drug repurposing may offer an expedited route to the clinical translation of approved drugs effective for treating both meningioma and vestibular schwannoma to benefit NF2-related schwannomatosis patients.

Targeting fibrotic pathways such as TGF-β, FGF, and PDGF signalling, with medications like nintedanib and pirfenidone, may help overcome the resistance mechanisms associated with MAPK inhibitor therapy. This review unravels the complex interactions between MAPK inhibitors and anti-fibrotic drugs in the treatment of melanoma, highlighting how they might work together to remodel the TME and overcome treatment resistance. Implementing this combinatorial method could lead to novel approaches for long-term melanoma control and provide a model for anti-fibrotic-based treatments for other solid cancers.

P2, N=20, Recruiting, University Hospital, Basel, Switzerland | Trial primary completion date: Aug 2025 --> Dec 2026 | Trial completion date: Aug 2025 --> Dec 2026

P=N/A, N=2000, Active, not recruiting, Boehringer Ingelheim | Initiation date: Jun 2023 --> Jun 2025

This is the first report of trametinib-nintedanib for a 57-year-old KRAS G12D-mutated recurrent pancreatic ductal adenocarcinoma. He had transient remission (lower CA19-9, stable lesions) but died of gastrointestinal bleeding, showing efficacy and bleeding risk.

These findings support the use of nintedanib in combination with radiotherapy as an effective, low-toxicity treatment strategy, highlighting the antitumor potential of ATF4-targeted agents.

P1, N=20, Not yet recruiting, Guangdong Hengrui Pharmaceutical Co., Ltd

All therapeutic agents-including the oncolytic adenovirus Ad5/3-D24-ICOSL-CD40L, cisplatin, paclitaxel, and nintedanib-were administered through flow-based circulation to more accurately replicate human pharmacokinetic conditions and tumor-drug interactions. This tumor-on-a-chip platform provides a physiologically relevant tool for real-time monitoring of treatment response, immune activation, and drug delivery under continuous flow. By bridging the gap between traditional in vitro models and in vivo studies, it offers a powerful preclinical system for optimizing combination regimens and advancing personalized therapies in ovarian cancer.